Atara Biotherapeutics Inc expected to post a loss of $1.93 a share - Earnings Preview

Atara Biotherapeutics

08/11/2024 23:14

* Atara Biotherapeutics Inc  ATRA.OQ   ATRA.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The Thousand Oaks California-based  company is expected to
report a 1,544.9% increase in revenue to $35.168 million from
$2.14 million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Atara Biotherapeutics
Inc is
for a loss of $1.93 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $14.00​, above​ its last closing price
of $10.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.38       -1.56      -3.10     Missed  -98.4
 Mar. 31 2024  -6.17       -6.41      -5.75     Beat    10.3
 Dec. 31 2023  -7.75       -12.05     -14.00    Missed  -16.2​
 Sep. 30 2023  -16.57      -16.55     -16.50    Beat    0.3
 ​​Jun.        -16.58      -16.81     -17.00    Missed  -1.1
 30 2023                                                
 Mar. 31 2023  -9.39       -9.79      -18.00    Missed  -83.8​
 Dec. 31 2022  -12.29      -12.69     -18.00    Missed  -41.8
 Sep. 30 2022  -19.24      -19.62     -20.50    Missed  -4.5
 This summary was machine generated November 8 at 23:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)